Status and phase
Conditions
Treatments
About
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Parts 1, 2, and 3 inclusion criteria:
Parts 1 and 3 inclusion criteria:
• Has histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor and has exhausted all standard of care treatment options
Part 2 inclusion criteria:
Exclusion criteria
Parts 1, 2, and 3 exclusion criteria:
Part 3 exclusion criteria:
Primary purpose
Allocation
Interventional model
Masking
73 participants in 3 patient groups
Loading...
Central trial contact
EU GSK Clinical Trials Call Center; US GSK Clinical Trials Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal